Is Hologic, Inc. overvalued or undervalued?

As of 5 February 2025, Hologic, Inc. has moved from a very attractive valuation grade to fair. The company appears to be fairly valued at this time. Key ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a ROE of 17.54%.
In comparison to its peers, Hologic's P/E ratio is slightly lower than the industry average, indicating it is on par with competitors. For instance, another peer has a P/E ratio of approximately 21.1, which aligns closely with Hologic's valuation. Despite recent stock performance lagging behind the S&P 500, particularly over the last year with a return of -11.82% compared to the S&P 500's 10.26%, the current valuation suggests that Hologic is neither undervalued nor overvalued at this point.